Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This retrospective study aims to quantify the relationship between 5-alpha-reductase
inhibitor (5ARI) adherence / length of therapy and the likelihood of acute urinary retention
(AUR) or prostate surgery in patients with benign prostatic hyperplasia (BPH) as well as the
economic impact associated with these medical encounters. The Integrated Health Care
Information Solutions (IHCIS) database will be utilized for this study (2000-2006).